SELLAS gains as mid-stage trial for leukemia drug succeeds
Source: SeekingAlpha
2025-07-15 08:22:32 ET
More on SELLAS Life Sciences
- Sellas Life Sciences: Tons Of Completed Studies
- Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit
- Seeking Alpha’s Quant Rating on SELLAS Life Sciences
- Historical earnings data for SELLAS Life Sciences
- Financial information for SELLAS Life Sciences
Read the full article on Seeking Alpha
For further details see:
SELLAS gains as mid-stage trial for leukemia drug succeeds
SELLAS Life Sciences Group Inc.
NASDAQ: SLS
SLS Trading
3.08% G/L:
$7.185 Last:
1,778,392 Volume:
$7.16 Open:
SLS Latest News
May 12, 2026 04:05:00 pm
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMarch 19, 2026 04:05:00 pm
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate UpdateSLS Stock Data
$535,597,063
140,448,048
1.12%
50
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
